Chinese biopharmaceutical company BrightGene Bio-Medical has raised $80 million in a pre-initial public offering (IPO) funding.
The round was led by Sequoia Capital China and HighLight Capital with participation from GF Qianhe.
BrightGene intends to use the funds for research and development.
In addition, the company plans to boost the capacity of its raw materials plant and build a production plant for complex injections.